Zydus gets USFDA nod for generic drug to treat multiple sclerosis

Zydus Lifesciences has secured USFDA approval to market Glatiramer Acetate Injection, a generic version of Copaxone, for treating relapsing forms of Multiple Sclerosis. Developed with Chemi S.p.A. and manufactured in Europe, the drug addresses a market with USD 719 million in annual sales in the US. This approval highlights Zydus' dedication to providing diverse therapeutic options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8K9ibp7
via IFTTT